In-depth analysis of the efficacy, mechanism of action and potential side effects of dasatinib

Dasatinib (Dasatinib), as an outstanding representative of BCR-ABL tyrosine kinase inhibitors, has shown significant effects in the treatment of acute lymphoblastic leukemia, chronic myelogenous leukemia and other leukemias.

Dasatinib demonstrated impressive efficacy in a study of patients with newly diagnosed chronic phase chronic myelogenous leukemia. During the 12-month treatment period, 76.8% of patients in the dasatinib group achieved complete cytogenetic response (CCyR), compared with 66.2% of patients in the imatinib group. In addition, dasatinib also performed well in terms of major molecular responses, with 52.1% of patients reporting a positive response to the drug, compared with 33.8% in the imatinib group.

Dasatinib has also demonstrated its unique efficacy in adult patients with chronic phase chronic myelogenous leukemia who have developed resistance or intolerance to imatinib. After at least 24 months of follow-up, 92% of patients treated with dasatinib achieved hematologic clinical remission within 4 weeks. Even more exciting is that among patients taking 100 mg of dasatinib daily, the cytogenetic response rate reached 63%, and the CCyR was as high as 50%.

The treatment durability of dasatinib is also relatively long-lasting. During at least 24 months of follow-up, 77% of patients randomly assigned to dasatinib were still receiving the drug, which was comparable to 75% of patients in the imatinib group. After longer follow-up (at least 60 months), 61% of patients in the dasatinib group and 62% of patients in the imatinib group remained on treatment.

It is worth mentioning that dasatinib is well tolerated, which allows patients to benefit from treatment with the drug for longer. Its in-depth mechanism of action is inseparable from its precise inhibition of BCR-ABL tyrosine kinase, which is also the key to dasatinib's ability to stand out in the treatment of leukemia.

Although dasatinib performs well in the treatment of leukemia, its potential side effects cannot be ignored. In clinical trials, a small number of patients developed Although the adverse reaction of QTc prolongation accounts for less than 1%, it still requires close attention. In addition, the use of dasatinib may be associated with side effects such as bone marrow suppression, bleeding-related events, fluid retention, and cardiovascular toxicity. Dasatinib may cause embryo-fetal toxicity, so pregnant and breastfeeding women should seek medical advice before use. At the same time, pediatric patients may experience adverse reactions related to bone growth and development when using dasatinib, and need to be closely monitored and the treatment plan adjusted.

In general, dasatinib is an effective leukemia treatment drug, and its efficacy and mechanism of action have been widely recognized. However, it is still necessary to pay close attention to its potential side effects during use and develop a personalized treatment plan according to the patient's condition.